Predicting emergent Dolutegravir resistance in South Africa:

2 A modelling study

Tom Loosli^{1,2}, Anthony Hauser^{1,2,3,4}, Johannes Josi^{1,2}, Nuri Han^{1,2}, Suzanne M Ingle⁵, Ard van Sighem⁶, Linda Wittkop^{7,8,9}, Janne Vehreschild^{10,11,12}, Francesca Ceccherini-Silberstein¹³, Gary Maartens¹⁴, M John Gill^{15,16}, Caroline A Sabin¹⁷, Leigh F Johnson¹⁸, Richard Lessells^{19,20}, Huldrych F Günthard^{1,2}, Matthias Egger^{3,5,18}, Roger D Kouyos^{1,2}

- 1. Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland (Tom Loosli Msc, Anthony Hauser PhD, Johannes Josi PhD, Nuri Han Msc, Prof Huldrych F Günthard MD, Prof Roger D Kouyos PhD)
- 2. Institute of Medical Virology, University of Zurich, Zurich, Switzerland (Tom Loosli, Anthony Hauser, Johannes Josi, Nuri Han, Prof Huldrych F Günthard, Prof Roger D Kouyos)
- 3. Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland (Anthony Hauser, Prof Matthias Egger MD)
- 4. INSERM, Sorbonne Université, Pierre Louis Institute of Epidemiology and Public Health, Paris, France (Anthony Hauser)
- 5. Population Health Sciences, Bristol Medical School, University of Bristol, UK (Suzanne M. Ingle PhD, Prof Matthias Egger)
- 6. Stichting hiv monitoring, Amsterdam, the Netherlands (Ard van Sighem PhD)
- 7. Univ. Bordeaux, INSERM, Institut Bergonié BPH U1219, CIC-EC 1401, Bordeaux, F-33000, France (Prof Linda Wittkop PhD)
- 8. INRIA SISTM Team, Talence, France (Prof Linda Wittkop)
- 19 9. CHU de Bordeaux, Service d'information Médicale, INSERM, Institut Bergonié, CIC-EC 1401, Bordeaux, F-33000, France
 20 (Prof Linda Wittkop)
 - 10. Department || of Internal Medicine, Hematology/Oncology, Goethe University, Frankfurt, Frankfurt Am Main, Germany (Prof Janne Vehreschild MD)
 - 11. Department | of | Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany (Prof Janne Vehreschild)
- 12. German Centre for Infection Research (DZIF), Partner Site Bonn® Cologne, Cologne, Germany (Prof Janne Vehreschild)
 13. Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy (Prof Francesca Ceccherin
 - 13. Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy (Prof Francesca Ceccherini-Silberstein PhD)
 - 14. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa (Prof Gary Maartens MD)
 - 15. Southern Alberta Clinic, Calgary, AB, Canada (Prof M John Gill MD)
 - 16. Department of Medicine, University of Calgary, Calgary, AB, Canada (Prof M John Gill)
 - 17. Institute for Global Health, University College London, UK (Prof Caroline A Sabin PhD)
- 18. Centre for Infectious Disease Epidemiology and Research, School of Public Health, University of Cape Town, Cape Town, South Africa (Prof Leigh F Johnson PhD, Prof Matthias Egger)
- 35 19. KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), University of KwaZulu-Natal, Durban, South Africa (Richard Lessells PhD)
 - 20. Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa (Richard Lessells)
- 39 Correspondence to:

1

3

4

9

10

11

12

13

14

15

16

17

18

21

22

23

24

27

28

29

30

31

37

38

- 40 Tom Loosli (tom.loosli@uzh.ch)
- 41 Roger Kouyos (roger.kouyos@uzh.ch)

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

Summary Background: In response to the rising prevalence of non-nucleoside reverse transcriptase inhibitors (NNRTIs) resistance, millions of people living with HIV (PWH) have switched to dolutegravir-based antiretroviral therapy (ART). Understanding the possible emergence of dolutegravir resistance is essential for health policy and planning. We developed a mathematical model to predict the trends of dolutegravir resistance in PWH in South Africa. Methods: MARISA (Modelling Antiretroviral drug Resistance In South Africa) is a deterministic compartmental model consisting of four layers: (i) the cascade of care, (ii) disease progression, (iii) gender, and (iv) drug resistance. MARISA was calibrated to reproduce the HIV epidemic in South Africa. We assumed dolutegravir was introduced in 2020. We extended the model by including key resistance mutations observed in PWH experiencing virologic failure on dolutegravir-based ART (G118K, E138AKT, G140ACS, Q148HKNR, N155H, and R263K). Model outcomes were acquired (ADR) and transmitted drug resistance (TDR) to dolutegravir and NNRTIs stratified by duration on failing dolutegravir-based ART and under different counterfactual scenarios of switching to proteaseinhibitor (PI)-based ART. Finding: The model predicts that ADR will increase rapidly, from 18.5% (uncertainty range 12.5% to 25.4%) in 2023 to 46.2% (32.9% to 58.9%) in 2040. The prevalence of ADR in 2040 increased with the duration of virologic failure on dolutegravir-based ART: 18.0% (12.2% to 23.7%) for 6 months of failing ART compared to 54.8% (41.1% to 63.9%) for over 1.5 years. For TDR, the model predicts a slow but steady increase from 0.1% (0.1% to 0.2%) in 2023 to 8.8% (4.4% to 17.3%) in 2040. Transmitted NNRTI resistance will cease to increase but remain prevalent at 7.7% in 2040. Rapid resistance testing-informed switching to PI-based ART would substantially reduce both ADR and TDR. Interpretation: The prevalence of dolutegravir ADR and TDR will likely increase, with the 10% threshold of TDR possibly reached by 2035, depending on monitoring and switching strategies. The increase will likely be greater in settings where resources for HIV-1 RNA monitoring and resistance testing or options for switching to alternative ART regimens are limited. Funding: Swiss National Science Foundation, National Institutes of Health, UZH URPP Evolution in Action

Research in context

Evidence before this study

Dolutegravir has demonstrated high efficacy, even in individuals with compromised backbone drugs. We searched Scopus on April 15 2024, using free text words dolutegravir and resistance. We did not identify any modelling studies attempting to predict dolutegravir resistance trends in the coming years. A recent collaborative analysis of predominantly European cohort studies involving 599 people living with HIV (PWH) who underwent genotypic resistance testing at the point of dolutegravir-based treatment failure showed that the risk of dolutegravir resistance increases significantly in the presence of Nucleoside Reverse Transcriptase Inhibitor (NRTI) resistance. This is particularly concerning in settings such as South Africa, where a high proportion of individuals already exhibit NRTI resistance. Indeed, recent surveys in South Africa already hint at rapidly

Added value of this study

increasing levels of acquired dolutegravir resistance.

This study is the first to model the likely dynamics of dolutegravir resistance in South Africa. Covering the period 2020 to 2040, it extends a previous model of antiretroviral drug resistance evolution in South Africa to dolutegravir-based ART. The results indicate that while dolutegravir resistance is currently low, it will increase at the population level, and transmitted dolutegravir resistance may exceed 10% by around 2035, depending on the duration PWH spend on failing dolutegravir-based ART. Interventions such as switching to protease-inhibitor (PI)-based ART based on genotypic resistance tests could reduce or even curb the rise of dolutegravir resistance.

Implications of all the available evidence

Dolutegravir resistance may undermine the success of integrase strand transfer inhibitor (INSTI)-based ART in South Africa, where the guidelines limit drug resistance testing to PWH with repeated viral load measurements above 1,000 copies/mL and evidence of good adherence. Monitoring the evolution of dolutegravir resistance at the population level is crucial to inform future changes in guidelines on drug resistance testing and switching to PI-based ART.

Introduction

101

102

103

104

105

106

107

108

109

110111

112

113

114

115

116

117

118

119120

121122

123

124125

126

127

128

129

In response to the rising prevalence of drug resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs), the World Health Organization (WHO) has recommended the integrase strand transfer inhibitor (INSTI) dolutegravir as first- and second-line antiretroviral therapy (ART) for all people living with HIV (PWH) since 2018. By July 2022, dolutegravir had been adopted as the preferred first-line ART in 108 countries, 2 including South Africa, where over 7.5 million people live with HIV.³ Dolutegravir-based ART has a higher genetic barrier to resistance than the previously recommended non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line regimens.⁴ Dolutegravir-resistant HIV is currently rare in PWH on first-line ART but is observed more frequently in treatment-experienced people in trials, boservational cohorts, 6,7 and national surveys, 8-10 A collaborative analysis of eight large cohort studies combined data from 599 individuals, primarily from Europe, who experienced viremia on dolutegravir-based ART and underwent genotypic resistance testing (GRT). At least one major or accessory INSTI drug resistance mutation (DRM) was found in 86 (14%) study participants, and 23 (3.8%) had high or intermediate levels of predicted resistance to dolutegravir.6 In South Africa, the current treatment guidelines recommend GRT only for people who have two or more viral load measurements exceeding 1,000 copies/mL and have been on dolutegravir-based or protease inhibitor (PI)- ART for over two years with good adherence. 11 Consequently, individuals often remain viremic for prolonged periods. 12-14 Furthermore, switching to alternative regimens, such as protease inhibitor (PI)-based regimens, is relatively uncommon among those on failing dolutegravir-based ART. 15 Together, these factors may facilitate the emergence and spread of HIV drug resistance. MARISA (Modelling Antiretroviral drug Resistance In South Africa) is a mathematical model that simulates the HIV epidemic and NNRTI resistance dynamics in South Africa. 16,17 We updated the model to include a dimension for dolutegravir resistance, allowing us to study the emergence of acquired and transmitted resistance to dolutegravir. We aimed to predict how dolutegravir resistance levels will change over time to assess if the drug will stay effective in the long run or if resistance will rise rapidly, similar to what happened with the NNRTIs.

Methods

130

131

132133

134

135

136

137

138

139

140

141

142

143

144

145

146

147148

149150

151152

153

154

155

156

157

158159

160

161

The MARISA model

Described in detail elsewhere, ¹⁶ MARISA is a deterministic compartmental model of the HIV-1 epidemic in South Africa from 2005 to 2040 using monthly time steps. Briefly, it consists of four dimensions: i) the continuum of care from HIV infection through to the diagnosis and initiation of ART, suppressive ART (viral load < 1'000 copies per ml) and failing ART (viral load \geq 1'000 copies per ml), and possible transfer to PI-based ART; ii) disease progression, with four CD4 count groups (> 500, 350 – 500, 200 – 349, and < 200 cells/µL); iii) gender; iv) drug resistance (appendix p3). MARISA was calibrated to reproduce the HIV epidemic in South Africa using data from the IeDEA collaboration¹⁸ and the literature and fitted to estimates of the demographic and epidemiological Thembisa model.¹⁹ We assumed the introduction of dolutegravir started in 2020. Rates of initiation and switching to dolutegravir-based ART are described elsewhere¹⁷ and in the appendix (p4-5).

The original implementation of MARISA treated resistance as two states (susceptible or resistant), which is appropriate for antiretroviral drugs with a low genetic barrier, such as NRTIs and NNRTIs. However, this approach is unsuitable for dolutegravir, which has a higher genetic barrier. 4 We included the drug resistance mutations observed in the DTG RESIST study, i.e., G118K, E138AKT, G140ACS, Q148HKNR, N155H, and R263K.6 These six DRMs cover all mutations identified as signature DRMs for dolutegravir resistance.²⁰ R263K was assumed to occur in isolation, whereas G140ACS and Q148HKNR, and G118R and E138K occurred in combination, in line with a recent review of acquired dolutegravir drug resistance mutations. ²⁰ The resulting genotypes (see Figure 1) were classified as susceptible, potential-low, low, intermediate, and high-level dolutegravir resistance according to the Stanford resistance algorithm. ²¹ As in Hauser et al., ^{16,17} we included resistance for NRTI and NNRTI (susceptible or resistant), resulting in total in 48 drug resistance compartments. We expanded the treatment cascade, stratifying the treatment failure compartments according to the average duration on failing ART (< 6 months, 6 months to 1.5 years, > 1.5 years). Finally, we modified the model to include out-of-care dynamics, whereby individuals on failing dolutegravir-based ART may leave and re-enter care (Figure 1). See appendix p6-7 for further details.

Definitions, parameters and calibration

We defined transmitted dolutegravir resistance as the proportion of people with intermediate or high levels of dolutegravir resistance at diagnosis. Acquired drug resistance was defined as the proportion of people on a failing dolutegravir-based regimen with intermediate or high-level dolutegravir resistance.

Key model parameters included (i) acquisition and (ii) reversion rates of dolutegravir resistance mutations, (iii) the impact of NRTI resistance on dolutegravir resistance acquisition, (iv) the impact of dolutegravir resistance on dolutegravir treatment efficacy, (v) the probability of transmission dolutegravir DRMs compared to NNRTI resistance transmission, and (vi) the proportion on failing dolutegravir-based ART with detectable drug levels. Based on the DTG RESIST study, 6 we assume that NRTI resistance increases the risk of acquiring dolutegravir DRMs upon treatment failure (appendix page 10). We estimated mutation-specific acquisition rates based on an estimated duration of 3 months of failing dolutegravir-based ART in the DTG RESIST study. The reversal of dolutegravir resistance mutations is not well documented but may occur rapidly.²² We assumed an average duration to reversion of two years for each mutation with HIV replicating in the absence of dolutegravir. We assumed that high- and intermediate-level dolutegravir resistance increases the treatment failure rate on dolutegravir-based ART: for high-level resistance, the impact is equal to that of high-level NNRTI resistance on NNRTI-based ART; for intermediate resistance, the effect is halved. The probability of transmitting dolutegravir resistance mutations in an HIV transmission event is unknown, but cases have been documented.²³ We assumed an equal transmission rate for dolutegravir resistant strains as for susceptible strains, and explored decreased rates in sensitivity analyses (allowing for up to 20 times decreased transmission rates in resistant strains). The parameters included in MARISA and its calibration are described in detail in the appendix (p4-11).

To construct plausible ranges of model outcomes (predicted dolutegravir ADR and TDR) that reflect the uncertainty in the choice of parameter values, we defined an uncertainty range using pessimistic (favouring the emergence of resistance) or optimistic (impeding the emergence of resistance) parameter values in addition to our baseline parameter isation (Table 1 and appendix p12).

Counterfactual scenarios

162

163

164

165

166

167

168169

170

171

172173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

In counterfactual scenarios, we investigate the impact of interventions such as those proposed in the RESOLVE trial²⁴ on transmitted and acquired dolutegravir resistance. Specifically, we compared our baseline scenario, where current treatment guidelines in South Africa are modelled, with two alternative scenarios, where measures to reduce dolutegravir resistance are modelled: i) upon entering failing dolutegravir compartments, people are switched to initiating PI-based ART within an average time of 6 or 12 months, and ii) upon an average time of 6 or 12 months on failing dolutegravir-based ART, people with intermediate or high level dolutegravir resistance are switched to PI-based ART within an average time of 6 months (representing the duration taken for druglevel-

to 11 based ART within an average time of 6 months (representing the daration taken for drugiever

and resistance testing, receiving results, and implementing treatment adjustments). These two modelled scenarios correspond closely to the RESOLVE interventions in which i) upon detection of viral failure on dolutegravir-based ART, all people are immediately switched to PI-based ART, and ii) upon detection of viral failure on dolutegravir-based ART, all people undergo drug-level- and resistance testing, followed by switch to PI-based ART in case of resistance, and continue on dolutegravir-based ART otherwise. The appendix (p15) provides further details on the scenarios.

Sensitivity analyses

We investigated the effects of mutation acquisition and reversion rates by varying viremia duration on dolutegravir-based ART rates from 2 to 6 months and the time for dolutegravir DRMs to revert to wild type from 6 months to 20 years. Further, we varied the hazard ratio for acquiring dolutegravir DRMs, comparing NRTI susceptible with resistant, from 1 (no impact) to 10. Similarly, we varied the hazard ratio for failing dolutegravir-based ART associated with high-level resistance from 2 to 4. We varied the probability of transmitting resistant strains from 100% (as likely as susceptible strain transmission) to 5% (20 times less likely than susceptible strain transmission). Finally, we varied the proportion of PWH with detectable drugs failing on dolutegravir-based ART from 0.3 to 1.

In addition to varying parameters one by one, we performed a multidimensional sensitivity analysis by implementing a Monte Carlo estimation of the first-order and total Sobol indices, ²⁵ which are quantitative measures to assess the importance of parameters (and their interactions in the case of total Sobol indices) on the variability of modelled outcomes. The indices help determine relative parameter importance and identify knowledge gaps (appendix p14, p16).

Role of the funding source

The funders of the study did not participate in the study design, data collection, data analysis, data interpretation, and writing of the report. The corresponding author had full access to the data of this study and had the final responsibility for the decision to submit for publication.

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

Results The model predicts a steep increase in the number of individuals on dolutegravir-based ART after its introduction in 2020, followed by a more modest but steady increase with numbers approaching eight million PWH on dolutegravir by 2040. The proportion with viral suppression in PWH on dolutegravir-based ART is estimated at around 93%, with those virally non-suppressed (viral load > 1'000 copies per ml) comprised of an increasing proportion with dolutegravir resistance (Figure 2). Among those on dolutegravir-based ART, CD4 levels continue to improve (appendix, p 14) Acquired and transmitted dolutegravir resistance The model predicts that acquired dolutegravir resistance in people with virologic failure on dolutegravir-based ART will increase rapidly, from 18.5% (uncertainty range 12.5% to 25.4%) in 2023 to 46.2% (uncertainty range 32.9% to 58.9%) in 2040 (Figure 2). There were substantial differences in the predicted levels of acquired dolutegravir resistance depending on the duration of failing dolutegravir-based ART, with a lower prevalence in people experiencing virologic failure for 6 months or less and a higher prevalence among those experiencing failure for over 1.5 years. For transmitted drug resistance, the model predicts a slow but steady increase from 0.1% (uncertainty range 0.1% to 0.2%) in 2023 to 8.8% (uncertainty range 4.4% to 17.3%) in 2040. The rise of transmitted NNRTI resistance will be broken by introducing dolutegravir, but transmitted NNRTI resistance will remain prevalent at 7.7% in 2040 (Figure 2) **Counterfactual scenarios** We find that reducing the duration PWH remain viraemic whilst on dolutegravir-based ART would substantially reduce acquired dolutegravir resistance at the population level. Immediately switching to PI-based ART upon detecting of viral failure may reduce acquired dolutegravir resistance levels by 2040 from 46.2% to 14.6% and 8.2%, depending on time to detection of viral failure. If using the mitigation strategy with GRT informed ART adjustment upon detection of viral failure, projected acquired dolutegravir resistance may be reduced to 11.3% and 6.3% (Figure 3). Transmitted dolutegravir resistance may be more than halved by 2040, from 8.8% to 2.1% and 1.1% in case of immediate switching to PI-based ART, or to 3.0% and 2.3% in case of GRT informed ART adjustment (Figure 3). Further details are available from the appendix (p15). Sensitivity analyses We assessed the impact of key model parameters one by one and also performed a multivariate sensitivity analysis. Perturbing one parameter at a time showed that dolutegravir resistance outcomes are affected by several variables, but the results from the main analysis were robust.

However, substantial deviations were observed for extreme parameter values, for example, assuming that the probability of transmission of dolutegravir resistance mutations was twenty times less likely than for NNRTIs, assuming much higher acquisition rates of dolutegravir resistance mutations or higher or lower reversion rates or proportion of people with detectable drug levels than in the main analysis. (appendix p16-18)

The variance-based global sensitivity analysis showed that predicted dolutegravir ADR was strongly influenced by assumptions regarding the proportion of people with detectable drug levels (Total Sobol' sensitivity index 0.34; 95% CI 0.30 to 0.38), and mutation acquisition rates (0.30; 95% CI 0.27 to 0.33). Assumptions for the impact of NRTI resistance on dolutegravir resistance acquisition and of dolutegravir resistance on efficacy also affected ADR predictions (0.19; 95% CI 0.17 to 0.21 and 0.16; 95% CI 0.14 to 0.18, respectively). The assumed dolutegravir DRM transmission probability compared to NNRTIs was the most important factor for the uncertainty in predicted dolutegravir TDR (0.64; 95% CI 0.56 to 0.70). Mutation reversion rates also affected TDR predictions (0.20; 95% CI 0.16 to 0.23).

Discussion

Summary of findings

The transition to dolutegravir-based antiretroviral therapy (ART) has contained NNRTI resistance as a threat to the long-term effectiveness of ART. Still, reliance on INSTIs for first-line and second-line ART and prevention of HIV transmission carries the risk of emerging drug resistance to dolutegravir. We updated MARISA, a mathematical model of antiretroviral drug resistance, to study the emergence of resistance to dolutegravir in South Africa. The model fitted the South African data well, with the modelled proportion of PWH with viral suppression (around 93%) in line with empirical data and the 92% estimate reported by UNAIDS. We found that the prevalence of acquired and transmitted dolutegravir resistance will likely increase. The 10% threshold of transmitted drug resistance, above which WHO recommends the replacement of a drug, could be reached by 2035, depending on the monitoring and switching strategies in place. During the same period, the prevalence of transmitted NNRTI will decline and then plateau at around 8%. Timely switching of PWH experiencing virologic failure to PI-based ART would substantially reduce acquired and transmitted drug resistance.

Modelled resistance in context with empirical data

Currently, viral suppression rates on dolutegravir are high. Although acquired drug resistance is rare, it can occur, especially in individuals with a compromised NRTI backbone. Transmission of dolutegravir resistance has also recently been documented. Programmatic data on dolutegravir resistance in resource-limited settings are scarce. Nationally representative HIV drug resistance surveys based on remnant routine diagnostic viral load samples in South Africa suggest increasing levels of dolutegravir resistance. Steegen *et al.* found that in samples with viral load >1000 copies/mL and detectable dolutegravir, resistance to dolutegravir increased from 2.7% in 2021 to 11.1% in 2022, consistent with our predictions. Similar proportions of PWH with resistance mutations on failing dolutegravir-based ART have been recently reported by Tschumi *et al.* in Lesotho, and by the WHO from other countries in Southern Africa.

Duration on failing regimen

Our model predicts that acquired resistance may increase relatively quickly in the coming years. However, the predicted increase in resistance strongly depends on how long people with HIV remain viraemic on a failing dolutegravir-based regimen. There are often delays in switching, and some PWH may not be switched at all. A study linking medical and laboratory data from PWH on first-line ART in 52 South African clinics from 2007 to 2018 reported that only about 40% of PWH with confirmed virological failure were switched. Among those who switched, the median time to

switch was about 16 months, with an interquartile range of 8 to 29 months. ²⁸ Similarly, an analysis of a South African private sector ART program found that the median time from virologic failure to switching to second-line ART was about 13 months (interquartile range 8 to 22 months), with delays in switching associated with increased mortality. ²⁹ Other studies from sub-Saharan Africa, including data from Central Africa, East Africa and West Africa, also found sub-optimal switching in adult HIV cohorts after virologic failure, with delays typically ranging from 4 to 17 months. ^{30–33}

Real-world evidence on effective switching strategies will come from the ongoing RESOLVE trial²⁴ in public-sector HIV clinics in Uganda and South Africa. The trial compares universal switching to Pl-based second-line ART with switching guided by genotypic resistance tests, urine tenofovir adherence assays, and standard of care. In line with the association between the time spent on a failing regimen and resistance development, the model shows that such resistance mitigation strategies involving rapid switching to PI-based ART could effectively curb the increase in acquired and slow down the increase in transmitted dolutegravir resistance. Both strategies could keep the prevalence of dolutegravir resistance below 10% throughout the modelled period, i.e. up to 2040, in case of switching or drugleveldrug level- and resistance testing, respectively, within 6 months after virologic failure. Of note, the total number of people on PI-based ART differs strongly between the two mitigation strategies. Implementing the immediate PI-switch strategy would result in almost half of all people on ART in South Africa on PI-based ART by 2040.

Strengths and limitations

Strengths of our study include the combination of modelling the population-level epidemiology of the HIV epidemic in South Africa and of INSTI, NNRTI and NRTI drug resistance, taking into account the differences in the genetic barrier of these drug classes, and the model parametrisation using data from a large collaborative study of dolutegravir resistance. Further, the model allowed us to assess the impact of public health interventions in counterfactual scenarios. Limitations include large parameter uncertainty, particularly regarding mutation pathways and acquisition- and reversion rates, which we addressed in the sensitivity analyses. The global sensitivity analysis helped unravel the relative importance of these parameters, and identified key knowledge gaps in our understanding of dolutegravir resistance dynamics. The limited data available on drug resistance mutation and their accumulation is a further limitation that may only be addressed in the future when more data becomes available. There is also uncertainty about the interactions between DRM's impact on viral fitness, including the role of compensatory mutations and the transmission of DRMs. This uncertainty affects transmitted drug resistance more than acquired, as reflected in the broader range of modelled outcomes for transmitted drug resistance. The assumed treatment cascade is a

simplification. For example, more complicated treatment histories or the dis- and re-engagement in care³⁴ that may favour the emergence of resistance were not explicitly modelled.

Conclusions

In conclusion, this modelling study indicates that dolutegravir resistance may increase considerably in South Africa: without changes in the management of virologic failure on dolutegravir-based ART, the emergence of transmitted dolutegravir resistance appears to be a question of when, not if, and acquired dolutegravir resistance may increase rapidly in the near future. Drug resistance mitigation strategies for those with virologic failure on dolutegravir-based ART, such as GRT-informed ART adjustment, could strongly reduce acquired and transmitted dolutegravir resistance if virologic failure is detected rapidly. We conclude that dolutegravir resistance surveillance including enhanced viral load monitoring and genotypic resistance testing should be strengthened, especially in settings with programmatic use of dolutegravir-based ART where people remain longer on failing ART. Greater access to genotypic resistance testing ³⁵ as well as low-cost rapid point-of-care tests of antiretroviral drug levels, ³⁶ and making generic darunavir/ritonavir available for around 200 US dollars per patient per year ³⁷ should increase rates of switching to second-line ART and reduce delays, and thereby curbing the emergence and spread of dolutegravir resistance.

Figures & Table

Table 1: Key dolutegravir resistance parameters. Modelled prospective scenarios include baseline parameter values, and ranges using pre-defined in- and decreased resistance parameters to derive an uncertainty interval. Other parameters used in the model can be found in the appendix p4-11. Abbreviations: DRM: drug resistance mutation.

			Uncertainty range	
Parameter	Description	Baseline	Pessimistic choice in parameter values	Optimistic choice in parameter values
1/r _{DRM}	Mean time for dolutegravir DRMs to revert (years)	2	3	2
$\alpha_{NRTI \rightarrow DTG}$	Impact of NRTI resistance on dolutegravir DRM acquisition rates (hazard ratio vs susceptible)	4	5	3
α _{impact DTG}	Impact of high-level dolutegravir resistance on dolutegravir efficacy (hazard ratio vs susceptible)	3.24	2	4
Фtransmission DTG	Probability of dolutegravir resistance transmission compared to NNRTI resistance transmission	Same	Same	-20%
Pdrug detect	Proportion with detectable drugs on failing dolutegravir-based ART	0.626	0.814	0.482

Note: For all scenarios, mutation rates were calculated based on assumed time of 3 months on failing dolutegravir-based ART (see appendix p7-8).




Figure 1: Simplified schematic overview of the adapted MARISA model. The treatment dimension, including dolutegravir resistance acquisition on failing dolutegravir-based ART, is shown. Not displayed here are the dimensions for gender and CD4 levels, NNRTI- and NRTI resistance acquisition, and mortality. Details on the model structure can be found in the appendix p3-11.




Figure 2: Modelled viral suppression on DTG-based ART, acquired and transmitted dolutegravir resistance. Solid lines show baseline parameterisation regarding mutation reversion rates, impact of NRTI resistance on dolutegravir DRM acquisition, impact of dolutegravir resistance on its efficacy, transmission probability of dolutegravir DRMs in an HIV transmission event, and proportion with detectable druglevelsdrug levels on failing dolutegravir-based ART. Shaded areas correspond uncertainty intervals (see appendix p12). Dolutegravir rollout was started in 2020. Viral suppression (viral load below 1'000 copies per ml) on dolutegravir-based ART is high; depending on the model assumptions for dolutegravir resistance (see uncertainty range), between 6% and 8% of people on dolutegravir-based ART may be virally unsuppressed. Acquired dolutegravir resistance is defined as proportion of people on a failing dolutegravir-based ART with intermediate-or high-level dolutegravir resistance. Transmitted dolutegravir resistance is defined as proportion of newly diagnosed people with intermediate- or high-level dolutegravir resistance.




Figure 3: Counterfactual scenario, modelling resistance emergence mitigation strategies. Both strategies reduce the duration with viremia on dolutegravir-based ART. GRT-informed ART adjustment includes druglevel testing and genotypic resistance testing upon detecting virologic failure, followed by switching to PI-based ART in case of intermediate or high level dolutegravir resistance. Immediate PI switch includes switching people with virologic failure on dolutegravir-based ART immediately to PI-based ART. Modelled scenarios include projections assuming 6 and 12 months until virologic failure is detected (6 months: dark blue and dark red lines; 12 months: light blue and light red lines) upon which the respective strategy is implemented immediately. In case of drugleveldrug level-and genotypic resistance testing, we assume an additional average duration of 6 months from detection of virologic failure to informed treatment adjustment. Acquired dolutegravir resistance is defined as proportion of people on a failing dolutegravir-based ART with intermediate- or high-level dolutegravir resistance. Transmitted dolutegravir resistance is defined as proportion of newly diagnosed people with intermediate- or high-level dolutegravir resistance.

Authors' contributions

392393

394

395

396

397

398

399

400 401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418 419

420

421

422

423

RDK, RL, ME, and HFG conceptualised the study. TL, JJ, and RDK curated the data. TL, AH, JJ, and RDK devised the methodology. TL, NH, and JJ conducted the formal analysis and validation. TL, NH, and JJ managed the data. RDK provided project administration. AH and ME contributed resources. TL, NH, and JJ applied and adapted the software. HFG, RL, ME, LFJ, AH, and RDK provided supervision. TL created the figures. TL and RDK wrote the original draft of the manuscript. All authors reviewed the manuscript. TL, NH and RDK have directly accessed and verified the underlying data reported in the manuscript. All authors had the final responsibility for the decision to submit for publication.

Declaration of interests

RDK reports grants from the Swiss National Science Foundation, the National Institutes of Health, and Gilead Sciences. MJG has served as an ad hoc advisor to Gilead, ViiV and Merck, RDK reports grants from the Swiss National Science Foundation, the National Institutes of Health, and Gilead Sciences, H. F. G. has received grants from the Swiss National Science Foundation, Swiss HIV Cohort Study, Yvonne Jacob Foundation, University of Zurich's Clinical Research Priority Program, Zurich Primary HIV Infection, Systems.X, Bill and Melinda Gates Foundation, NIH, Gilead Sciences, ViiV and Roche; personal fees from Merck, Gilead Sciences, ViiV, Janssen, GSK, Johnson & Johnson, and Novartis for consultancy or data and safety monitoring board membership; and a travel grant from Gilead. LW has received grants from the ANRS emerging infectious diseases ANRS MIE, European Union (projects funded via H2020, Horizon Europe). SMI reports grant funding by the NIH National Institute on Alcohol Abuse and Alcoholism (U01-AA026209, payment to institution). F.C.S has received grants from the Italian Istituto Superiore di Sanità, Italian Ministry of Health, Italian Ministry of University and Scientific Research, University of Rome Tor Vergata, European Union (projects funded via H2020, Horizon Europe), ViiV Healthcare, Gilead Sciences, Inc, and Merck Sharp & Dohme, Inc.; personal fees for consultancy from ViiV Healthcare, Gilead Sciences, Inc, and Merck Sharp & Dohme, Inc. All other authors declare no competing interests.

Acknowledgements

This work was supported by the University Research Priority Program 'Evolution in Action', the Swiss National Science Foundation (324730_207957), and the NIH National Institute of Allergy and Infectious Diseases under award number R01AI152772. We thank the DTG RESIST study group for helpful discussions.

References

424

- 425 1. WHO. Update of recommendations on first- and second-line antiretroviral regimens. Geneva, 426 Switzerland: World Health Organization; WHO. 2019. p. 3.
- 427 2. WHO. WHO HIV Policy Adoption and Implementation Status in Countries [Internet]. HIV 428 Treatment and Care Fact Sheet. 2022. p. 1–6. Available from:
- https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/who-hiv-policy-adoption-and-implementation-status-in-countries_nov.pdf?sfvrsn=bb35e6ae_8
- 431 [Accessed: 18.04.2023]
- 432 3. UNAIDS. Global HIV & amp; AIDS statistics 2020 fact sheet | UNAIDS [Internet]. [cited 2020 433 Jul 10]. Available from: https://www.unaids.org/en/resources/fact-sheet
- 434 4. Llibre JM, Pulido F, García F, García Deltoro M, Blanco JL, Delgado R. Genetic barrier to resistance for dolutegravir. AIDS Rev. 2015;17(1):56–64.
- 436 5. Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, et al. Efficacy and safety
 437 of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or
 438 tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a
 439 prospective, multicentre, open-label, factorial, randomised, no. Lancet HIV. 2022;1–13.
- 440 6. Loosli T, Hossmann S, Ingle SM, Okhai H, Kusejko K, Mouton J, et al. HIV-1 drug resistance in 441 people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis. Lancet 442 HIV. 2023 Oct 10;
- Tschumi N, Lukau B, Tlali K, Motaboli L, Kao M, Kopo M, et al. Emergence of acquired
 dolutegravir resistance in treatment-experienced people with HIV in Lesotho. Clin Infect Dis.
 2024 Apr;
- 446 8. Kamori D, Barabona G, Rugemalila J, Maokola W, Masoud SS, Mizinduko M, et al. Emerging 447 integrase strand transfer inhibitor drug resistance mutations among children and adults on 448 ART in Tanzania: findings from a national representative HIV drug resistance survey. J 449 Antimicrob Chemother. 2023;78(3):779–87.
- Steegen K. Close monitoring of dolutegravir resistance in patients with laboratory confirmed
 dolutegravir exposure: observations from a national HIV drug resistance survey in South
 Africa. Cape Town: XXX INTERNATIONAL WORKSHOP ON HIV DRUG RESISTANCE AND
 TREATMENT STRATEGIES; 2023.
- 454 10. WHO. HIV drug resistance: brief report 2024. Geneva: World Health Organization; 2024.
- 455 11. South African National Department of Health. 2023 ART Clinical Guidelines for the
 456 Management of HIV in Adults, Pregnancy and Breastfeeding, Adolescents, Children, Infants
 457 and Neonates. 2023;
- 458 12. Chimukangara B, Lessells RJ, Sartorius B, Gounder L, Manyana S, Pillay M, et al. HIV-1 drug 459 resistance in adults and adolescents on protease inhibitor-based antiretroviral therapy in 460 KwaZulu-Natal Province, South Africa. J Glob Antimicrob Resist. 2022;29:468–75.
- 461 13. Fox MP, Cutsem G V, Giddy J, Maskew M, Keiser O, Prozesky H, et al. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J
 463 Acquir Immune Defic Syndr. 2012;60(4):428–37.
- 464 14. Manasa J, Lessells RJ, Skingsley A, Naidu KK, Newell M-L, McGrath N, et al. High-Levels of
 465 Acquired Drug Resistance in Adult Patients Failing First-Line Antiretroviral Therapy in a Rural
 466 HIV Treatment Programme in KwaZulu-Natal, South Africa. PLoS One. 2013;8(8).

The freatment Flogramme in Kwazulu-Natal, South Africa. Flos Offe. 2013,8(8).

- 467 15. Venter WDF, Kaiser B, Pillay Y, Conradie F, Gomez GB, Clayden P, et al. Cutting the cost of 468 South African antiretroviral therapy using newer, safer drugs. Vol. 107, SAMJ: South African 469 Medical Journal. scieloza; 2017. p. 28-30.
- 470 16. Hauser A, Kusejko K, Johnson LF, Wandeler G, Riou J, Goldstein F, et al. Bridging the gap 471 between hiv epidemiology and antiretroviral resistance evolution: Modelling the spread of 472 resistance in south africa. PLoS Comput Biol. 2019;15(6):1–17.
- 473 17. Hauser A, Kusejko K, Johnson LF, Günthard HF, Riou J, Wandeler G, et al. Impact of scaling up 474 dolutegravir on antiretroviral resistance in South Africa: A modeling study. PLoS Med. 475 2020;17(12).
- 476 18. Chammartin F, Dao Ostinelli CH, Anastos K, Jaquet A, Brazier E, Brown S, et al. International 477 epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012-2019. BMJ 478 Open. 2020;10(5).
- 479 19. Johnson LF, Dorrington R. Thembisa version 4.1: A model for evaluating the impact of 480 HIV/AIDS in South Africa [Internet]. 2018. Available from:
- 481 https://www.thembisa.org/publications
- 482 20. Tao K, Rhee S-Y, Chu C, Avalos A, Ahluwalia AK, Gupta RK, et al. Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid 483 484 Scoping Review, Viruses, 2023;15(9).
- 485 21. Rhee S-Y, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency 486 virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 487 2003;31(1):298-303.
- 488 22. Canducci F, Barda B, Ceresola E, Spagnuolo V, Sampaolo M, Boeri E, et al. Evolution patterns 489 of raltegravir-resistant mutations after integrase inhibitor interruption. Clin Microbiol Infect. 490 2011;17(6):928-34.
- 491 23. François K, Van Onacker JD, Jordan MR, Journel I, Buteaue J, Pierre E, et al. First case report 492 of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with 493 tenofovir/lamivudine/dolutegravir use in mothers. AIDS. 2023;37(13):2097-9.
- 494 24. McCluskey S. A Randomized Clinical Trial to Evaluate Solutions for the Management of 495 Virologic Failure on TLD in Sub-Saharan Africa (RESOLVE) [Internet]. ClinicalTrials.gov. 496 Bethesda (MD): National Library of Medicine (US); [cited 2024 Jul 15]. Available from: 497
- https://classic.clinicaltrials.gov/ct2/show/NCT05373758
- 498 25. Saltelli A, Annoni P, Azzini I, Campolongo F, Ratto M, Tarantola S. Variance based sensitivity 499 analysis of model output. Design and estimator for the total sensitivity index. Comput Phys 500 Commun. 2010;181(2):259-70.
- 501 26. Dorward J, Sookrajh Y, Khubone T, van der Molen J, Govender R, Phakathi S, et al. 502 Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for 503 people with HIV in South Africa: a retrospective cohort study. Lancet HIV. 2023;10(5):e284-504 94.
- 505 27. UNAIDS: Joint United Nations Programme On HIV/AIDS. UNAIDS data 2023. Geneva; 2023.
- 506 28. Hermans LE, Carmona S, Nijhuis M, Tempelman HA, Richman DD, Moorhouse M, et al. 507 Virological suppression and clinical management in response to viremia in South African HIV 508 treatment program: A multicenter cohort study. PLoS Med. 2020;17(2):e1003037.
- 509 29. Bell Gorrod H, Court R, Schomaker M, Maartens G, Murphy RA. Increased Mortality with

510 Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South Africa. J Acquir 511 Immune Defic Syndr. 2020;84(1):107-13. 512 30. Petersen ML, Tran L, Geng EH, Reynolds SJ, Kambugu A, Wood R, et al. Delayed switch of 513 antiretroviral therapy after virologic failure associated with elevated mortality among HIV-514 infected adults in Africa. AIDS. 2014;28(14):2097-107. 515 31. Ssempijja V, Nakigozi G, Chang L, Gray R, Wawer M, Ndyanabo A, et al. Rates of switching to 516 second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, 517 and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda. 518 BMC Infect Dis. 2017;17(1). 519 32. Haas AD, Keiser O, Balestre E, Brown S, Bissagnene E, Chimbetete C, et al. Monitoring and 520 switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: 521 Collaborative analysis. Lancet HIV. 2015;2(7):e271-8. 522 33. Laurent C, Kouanfack C, Laborde-Balen G, Aghokeng AF, Mbougua JBT, Boyer S, et al. 523 Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical 524 monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall 525 ANRS 12110/ESTHER): A randomised non-inferiority trial. Lancet Infect Dis. 2011;11(11):825-526 33. 527 34. Euvrard J, Timmerman V, Keene CM, Phelanyane F, Heekes A, Rice BD, et al. The cyclical 528 cascade of HIV care: Temporal care engagement trends within a population-wide cohort. 529 PLoS Med. 2024;21(5). 530 35. de Oliveira T, Baxter C. Investing in Africa's scientific future. Science. 2024 Mar 531 6;383(6678):eadn4168. 532 36. Dorward J, Lessells R, Govender K, Moodley P, Samsunder N, Sookrajh Y, et al. Diagnostic 533 accuracy of a point-of-care urine tenofovir assay, and associations with HIV viraemia and drug 534 resistance among people receiving dolutegravir and efavirenz-based antiretroviral therapy. J 535 Int AIDS Soc. 2023;26(9). 536 37. World Health Organization. Innovative agreement launches affordable, optimal second-line 537 HIV treatment in low- and middle-income countries [Internet]. 2021. Available from: 538 https://unitaid.org/news-blog/innovative-agreement-affordable-optimal-second-line-hiv-539 treatment/#en 540